4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물

    公开(公告)号:KR1020130075442A

    公开(公告)日:2013-07-05

    申请号:KR1020110143807

    申请日:2011-12-27

    Abstract: PURPOSE: A composition for preventing or curing the metabolic syndrome related-diseases is provided to prevent or cure metabolic syndrome-related diseases including the obesity the hyperlipidemia, the hypertension, the arteriosclerosis, or the hyperinsulinemia etc. by using a 4-hydroxytamoxifen analog (GSK5182) which suppresses a fat synthesis, lowering glucose levels in blood, reducing the total cholesterol in blood, and reducing body fat. CONSTITUTION: A pharmaceutical composition for preventing or curing metabolic syndrome related-diseases comprises the chemical formula 1 of 4-hydroxy tamoxifen analog or its pharmaceutically acceptable salt as an active ingredient. The composition additionally comprises a pharmaceutically acceptable carrier. The metabolic syndrome related-diseases are more than one selected from a group comprising the obesity, the hyperlipidemia, the hypertension, the arteriosclerosis, and the hyperinsulinemia. The composition suppresses accumulation of fat, and reduces size of fat cell and body fat. [Reference numerals] (AA) Weight; (BB) Fat weight; (CC) Before injection; (DD) After injection; (EE,GG,KK,JJ) Control group; (FF,HH,LL) GSK5182 injected group; (II) Fat ratio

    Abstract translation: 目的:提供一种用于预防或治愈代谢综合征相关疾病的组合物,以通过使用4-羟基多莫司芬类似物(以下简称为“高血压”,“ GSK5182),其抑制脂肪合成,降低血液中的葡萄糖水平,降低血液中的总胆固醇并减少体脂肪。 构成:用于预防或治愈代谢综合征相关疾病的药物组合物包含4-羟基三苯氧胺类似物或其药学上可接受的盐作为活性成分的化学式1。 该组合物另外包含药学上可接受的载体。 代谢综合征相关疾病多于选自肥胖症,高脂血症,高血压,动脉硬化和高胰岛素血症的组。 该组合物抑制脂肪的积聚,并减少脂肪细胞和体脂肪的大小。 (标号)(AA)重量; (BB)脂肪重量; (CC)注射前; (DD)注射后; (EE,GG,KK,JJ)对照组; (FF,HH,LL)GSK5182注射组; (二)脂肪比例

    4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 간질환의 치료 또는 예방용 조성물
    12.
    发明公开
    4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 간질환의 치료 또는 예방용 조성물 有权
    用于治疗或预防包含4-羟基酪氨酸类似物或其药学上可接受的盐作为有效成分的肝脏失败的组合物

    公开(公告)号:KR1020120134939A

    公开(公告)日:2012-12-12

    申请号:KR1020110054178

    申请日:2011-06-03

    Abstract: PURPOSE: A composition containing a 4-hydroxy tamoxifen analog for preventing or treating liver diseases is provided to reduce GOT(glutamyl oxaloacetic transaminase) and GPT(glutamyl pyruvate transaminase) level and to prevent and treat liver diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating liver diseases contains a 4-hydroxy tamoxifen analog of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition additionally contains a pharmaceutically acceptable carrier. The liver diseases are non-alcoholic or alcoholic fatty liver. The pharmaceutical composition reduces fat accumulation in the liver. The non-alcoholic fatty liver is non-alcoholic steatohepatitis or late phase fibrosis liver diseases. A food composition for preventing or treating liver diseases contains 4-hydroxy tamoxifen analog of chemical formula 1 or sitologically acceptable salt thereof as an active ingredient.

    Abstract translation: 目的:提供含有用于预防或治疗肝脏疾病的4-羟基三苯氧胺类似物的组合物,用于减少GOT(谷氨酰氧乙酰转氨酶)和GPT(戊酰丙酮酸转氨酶)水平,并预防和治疗肝脏疾病。 构成:用于预防或治疗肝脏疾病的药物组合物含有化学式1的4-羟基他莫昔芬类似物或其药学上可接受的盐作为活性成分。 药物组合物另外含有药学上可接受的载体。 肝脏疾病是非酒精性或酒精性脂肪肝。 该药物组合物可减少肝脏中的脂肪堆积。 非酒精性脂肪肝是非酒精性脂肪性肝炎或晚期纤维化肝病。 用于预防或治疗肝脏疾病的食物组合物含有化学式1的4-羟基三苯氧胺类似物或其可以使用的盐作为活性成分。

    4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
    13.
    发明公开
    4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물 有权
    用于治疗或预防包含4-羟基酪氨酸类似物或药物可接受的作为有效成分的药物的糖尿病的组合物

    公开(公告)号:KR1020120073944A

    公开(公告)日:2012-07-05

    申请号:KR1020100135875

    申请日:2010-12-27

    Abstract: PURPOSE: A composition containing GSK5182 for preventing or treating diabetes is provided to suppress glucose generation gene expression and to lower glucose levels in blood. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes contains a 4-hydroxy tamoxifen derivative of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition additionally contains a pharmaceutically acceptable carrier. The pharmaceutical composition reduces glucose levels in blood. A food composition for preventing or treating diabetes contains the derivative thereof or a sitologically acceptable salt thereof as an active ingredient.

    Abstract translation: 目的:提供含有GSK5182用于预防或治疗糖尿病的组合物,以抑制葡萄糖生成基因表达并降低血液中的葡萄糖水平。 构成:用于预防或治疗糖尿病的药物组合物含有化学式1的4-羟基他莫昔芬衍生物或其药学上可接受的盐作为活性成分。 药物组合物另外含有药学上可接受的载体。 药物组合物降低血液中的葡萄糖水平。 用于预防或治疗糖尿病的食品组合物含有其衍生物或作为有效成分的可以使用的盐。

    링커를 통한 단백질 G와 항체의 결합체
    14.
    发明公开
    링커를 통한 단백질 G와 항체의 결합체 有权
    蛋白G链接器连接使用链接器

    公开(公告)号:KR1020160053609A

    公开(公告)日:2016-05-13

    申请号:KR1020140152894

    申请日:2014-11-05

    Inventor: 박승범 박한검

    CPC classification number: C07K14/315 C07K14/195 C12N15/11 G01N33/53

    Abstract: 본발명은단백질 G-링커결합체, 상기단백질 G-링커결합체가고체지지물질의표면에결합된바이오칩또는바이오센서, 및바이오칩또는바이오센서를이용하여항원을분석하는방법에관한것이다. 본발명의단백질 G-링커결합체로인해항체의방향성을조절하면서선택적으로표지가가능하게되어, 항원-항체결합부위를방해하지않으면서항체를센서표면에고정할수 있다.

    Abstract translation: 本发明涉及蛋白质G-接头缀合物,生物芯片或生物传感器,其上蛋白质G-接头缀合物与固体支持材料的表面结合,以及使用生物芯片或生物传感器分析抗原的方法。 蛋白质G-接头缀合物能够在调节抗体取向的同时实现选择性标记。 因此,可以将抗体固定在传感器的表面上,而不会阻塞抗原和抗体的结合位点。

    헤테로바이아릴피리딘 유도체 화합물의 제조방법 및 이러한 방법에 의해 제조된 헤테로바이아릴피리딘 유도체 화합물
    17.
    发明公开
    헤테로바이아릴피리딘 유도체 화합물의 제조방법 및 이러한 방법에 의해 제조된 헤테로바이아릴피리딘 유도체 화합물 有权
    制备异丁基吡啶衍生化合物的方法和其制备的异丁基吡啶衍生化合物

    公开(公告)号:KR1020110062351A

    公开(公告)日:2011-06-10

    申请号:KR1020090119049

    申请日:2009-12-03

    Inventor: 박승범 이상희

    Abstract: PURPOSE: A method for preparing hetero-biaryl pyridine derivative compounds is provided to easily produce the compounds and to suppress tumor cell proliferation. CONSTITUTION: A method for preparing hetero-biaryl pyridine derivative compound of chemical formula 1 comprises a step of reacting a compound of chemical formula 2 with a compound of chemical formula 3 in a polar protic solvent under the presence of acid catalyst. The polar protic solvent is methanol, ethanol, dichloroethane, dimethyl formamide, or mixture thereof. The acid catalyst is AlCl_3, AcOH, formic acid, trifluoroacetic acid(TFA), or HCl.

    Abstract translation: 目的:提供制备异环联吡啶衍生物化合物的方法,以容易地制备化合物并抑制肿瘤细胞增殖。 构成:化学式1的异联吡啶衍生物化合物的制备方法包括使化学式2的化合物与化学式3化合物在极性质子溶剂中在酸催化剂存在下反应的步骤。 极性质子溶剂是甲醇,乙醇,二氯乙烷,二甲基甲酰胺或其混合物。 酸催化剂是AlCl 3,AcOH,甲酸,三氟乙酸(TFA)或HCl。

    카바모일레이티드 우레탄 화합물을 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
    18.
    发明授权
    카바모일레이티드 우레탄 화합물을 포함하는 신경염증성 질환의 예방 또는 치료용 조성물 有权
    用于预防或治疗神经炎症疾病的组合物,包括氨基甲酰化的尿烷化合物

    公开(公告)号:KR101733578B1

    公开(公告)日:2017-05-08

    申请号:KR1020160049177

    申请日:2016-04-22

    CPC classification number: A61K31/42

    Abstract: 본발명은카바모일레이티드우레탄화합물을포함하는신경염증성질환의예방또는치료용조성물에관한것으로, 보다상세하게는미세아교세포(microglia) 또는성상교세포의활성을억제하는효과, 일산화질소(NO) 및 TNF-α의생성을억제하는효과, IL-1β및 iNOS 유전자의발현을억제하는효과를나타내는카바모일레이티드우레탄화합물을포함하는신경염증성질환의예방또는치료용조성물에관한것이다. 본발명에따른카바모일레이티드우레탄화합물은상기와같은효과를나타내어신경염증성질환의예방또는치료에유용하게사용될수 있다.

    Abstract translation: 本发明的氨基甲酰基联合涉及一种组合物用于预防或治疗神经系统的炎性疾病,其包括氨基甲酸酯化合物,更具体地,小胶质细胞(小胶质细胞),或作用,一氧化二氮,以抑制星形细胞的活性(NO) 并用于预防或治疗神经性炎性疾病,包括丙交酯表示抑制的效果的表达的效果的氨基甲酰基射线氨基甲酸酯化合物组合物,IL-1β和iNOS基因抑制产生TNF-α的。 根据本发明的氨基甲酰化氨基甲酸酯化合物显示出上述效果并且可以有效地用于预防或治疗神经炎性疾病。

    단백질 동정 방법
    20.
    发明授权
    단백질 동정 방법 有权
    鉴定蛋白质的方法

    公开(公告)号:KR101427328B1

    公开(公告)日:2014-08-06

    申请号:KR1020130029279

    申请日:2013-03-19

    CPC classification number: G01N33/582 G01N27/447 G01N33/68

    Abstract: Provided of the present invention is a method for identifying a target protein of a physiologically active low molecular compound using a probe and a negative probe labeled with fluorescents having different wavelengths. The probe can be conjugated with a target protein binding to the physiologically active low molecular material and also be conjugated with proteins not binding to the physiologically active low molecular material. Therefore, a negative prove labeled with a fluorescent of a wavelength different from a fluorescent conjugated with the probe can be used, or a physiologically active low molecular substance and the probe can be also used.

    Abstract translation: 本发明提供了使用探针和用不同波长的荧光标记的阴性探针鉴定生理活性低分子化合物的靶蛋白的方法。 探针可以与结合生理活性低分子材料的靶蛋白缀合,并且与不结合生理活性低分子材料的蛋白质缀合。 因此,可以使用用与探针结合的荧光波长不同的荧光标记的阴性证明,也可以使用生理活性低分子物质和探针。

Patent Agency Ranking